Adaptor Protein-3 Produces Synaptic Vesicles that Release Phasic Dopamine.

Biological Sciences Neuroscience VPS41 adaptor protein-3 (AP-3) phasic dopamine reinforcement learning synaptic vesicles vesicular monoamine transporter 2 (VMAT2)

Journal

bioRxiv : the preprint server for biology
Titre abrégé: bioRxiv
Pays: United States
ID NLM: 101680187

Informations de publication

Date de publication:
08 Aug 2023
Historique:
pubmed: 23 8 2023
medline: 23 8 2023
entrez: 23 8 2023
Statut: epublish

Résumé

The burst firing of midbrain dopamine neurons releases a phasic dopamine signal that mediates reinforcement learning. At many synapses, however, high firing rates deplete synaptic vesicles (SVs), resulting in synaptic depression that limits release. What accounts for the increased release of dopamine by stimulation at high frequency? We find that adaptor protein-3 (AP-3) and its coat protein VPS41 promote axonal dopamine release by targeting vesicular monoamine transporter VMAT2 to the axon rather than dendrites. AP-3 and VPS41 also produce SVs that respond preferentially to high frequency stimulation, independent of their role in axonal polarity. In addition, conditional inactivation of VPS41 in dopamine neurons impairs reinforcement learning, and this involves a defect in the frequency dependence of release rather than the amount of dopamine released. Thus, AP-3 and VPS41 promote the axonal polarity of dopamine release but enable learning by producing a novel population of SVs tuned specifically to high firing frequency that confers the phasic release of dopamine.

Identifiants

pubmed: 37609166
doi: 10.1101/2023.08.07.552338
pmc: PMC10441354
pii:
doi:

Types de publication

Preprint

Langues

eng

Subventions

Organisme : NIDA NIH HHS
ID : F32 DA051135
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA035821
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS095809
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS103938
Pays : United States

Commentaires et corrections

Type : UpdateIn

Déclaration de conflit d'intérêts

Competing interests: RHE is a consultant for Nine Square Therapeutics. The authors declare that they have no other competing interests.

Auteurs

Shweta Jain (S)

Department of Physiology, UCSF School of Medicine, San Francisco USA.
Department of Neurology, UCSF School of Medicine, San Francisco USA.

Andrew G Yee (AG)

Department of Pharmacology, University of Colorado School of Medicine, Aurora USA.

James Maas (J)

Department of Physiology, UCSF School of Medicine, San Francisco USA.
Department of Neurology, UCSF School of Medicine, San Francisco USA.

Sarah Gierok (S)

Department of Physiology, UCSF School of Medicine, San Francisco USA.
Department of Neurology, UCSF School of Medicine, San Francisco USA.

Hongfei Xu (H)

Department of Physiology, UCSF School of Medicine, San Francisco USA.
Department of Neurology, UCSF School of Medicine, San Francisco USA.

Jasmine Stansil (J)

Department of Neurology, UCSF School of Medicine, San Francisco USA.

Jacob Eriksen (J)

Department of Physiology, UCSF School of Medicine, San Francisco USA.
Department of Neurology, UCSF School of Medicine, San Francisco USA.

Alexandra Nelson (A)

Department of Neurology, UCSF School of Medicine, San Francisco USA.

Katlin Silm (K)

Department of Physiology, UCSF School of Medicine, San Francisco USA.
Department of Neurology, UCSF School of Medicine, San Francisco USA.

Christopher P Ford (CP)

Department of Pharmacology, University of Colorado School of Medicine, Aurora USA.

Robert H Edwards (RH)

Department of Physiology, UCSF School of Medicine, San Francisco USA.
Department of Neurology, UCSF School of Medicine, San Francisco USA.

Classifications MeSH